Clinical Impacts of Histological Subtyping Primary Breast Cancer

被引:0
|
作者
Fritz, P. [1 ,6 ]
Klenk, S. [1 ]
Goletz, S. [1 ]
Gerteis, A. [3 ]
Simon, W. [3 ]
Brinkmann, F. [5 ]
Heidemann, E. [5 ]
Luetttgen, E. [2 ]
Ott, G. [2 ]
Alscher, M. D. [1 ]
Schwab, M. [6 ]
Dippon, J. [4 ]
机构
[1] Inst Digital Med, Stuttgart, Germany
[2] Robert Bosch Krankenhaus, Dept Clin Pathol, Stuttgart, Germany
[3] Robert Bosch Krankenhaus, Dept Gynecol, Stuttgart, Germany
[4] Univ Stuttgart, Fachbereich Math, Inst Stochast & Anwendung, Stuttgart, Germany
[5] Onkol Schwerpunkt Stuttgart, Stuttgart, Germany
[6] Klin Pharmakol Stuttgart, Margarethe Fischer Bosch Inst, Stuttgart, Germany
关键词
Breast cancer; histology; survival analysis; steroid receptors; INVASIVE LOBULAR CARCINOMA; SURVIVAL; TERM; CHEMOTHERAPY; THERAPY; STAGE;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Treatment decisions in breast cancer depend on TNM classification and the assessment of additional variables with have an impact on survival. We examined whether histological subtyping breast cancer as either ductal or lobular is related to disease outcome. Patients and Methods: We examined a large data base of 14198 breast cancer patients. Results: Histological sub-classification of invasive breast cancer as either ductal or lobular is not correlated with disease outcome. However, the data further showed that invasive lobular carcinomas have a higher probability of being oestrogen receptor (ER)and progesterone receptor (PR)-positive and a lower probability of being c-erbB2-positive. They also showed a higher average age at the time of diagnosis in comparison with invasive ductal carcinoma. Local recurrence rates were lower in invasive lobular carcinoma in comparison with invasive ductal carcinoma (3.5% vs. 6.2%; p=0.031). The multivariable Cox regression analysis showed that ER, PR, nodal status, grade and tumour size predicted disease outcome with statistical significance, while the histological subtype (invasive ductal or lobular) was not a significant predictor of disease outcome. Conclusion: Histological sub-classification of invasive breast cancer as either ductal or lobular is not correlated with disease outcome. On the other hand our data gives some indication that lobular and ductal breast cancer appear to be different biological entities.
引用
收藏
页码:5137 / 5144
页数:8
相关论文
共 50 条
  • [31] HISTOLOGICAL REGRESSION OF BREAST-CANCER AFTER PRIMARY (NEOADJUVANT) CHEMOTHERAPY
    SINN, HP
    SCHMID, H
    JUNKERMANN, H
    HUOBER, J
    LEPPIEN, G
    KAUFMANN, M
    BASTERT, G
    OTTO, HF
    GEBURTSHILFE UND FRAUENHEILKUNDE, 1994, 54 (10) : 552 - 558
  • [32] INVESTIGATION OF HISTOLOGICAL ASSESSMENT OF VASCULAR INVASION IN PRIMARY BREAST-CANCER
    PINDER, S
    ELLIS, IO
    ELSTON, CW
    MITCHELL, A
    BLAMEY, RW
    JOURNAL OF PATHOLOGY, 1990, 161 (04): : A352 - A352
  • [33] MammaPrint and BluePrint in early breast cancer: Clinical implications of prognostic stratification and molecular subtyping
    Yao, K.
    Turk, M.
    Kaul, K.
    Wesseling, J.
    Stork-Sloots, L.
    de Snoo, F.
    Cristofanilli, M.
    CANCER RESEARCH, 2013, 73
  • [34] Update on the Use of Molecular Subtyping in Breast Cancer
    Lawton, Thomas J.
    ADVANCES IN ANATOMIC PATHOLOGY, 2023, 30 (06) : 368 - 373
  • [35] Molecular subtyping of male breast cancer by immunohistochemistry
    Kornegoor, Robert
    Verschuur-Maes, Anoek H. J.
    Buerger, Horst
    Hogenes, Marieke C. H.
    de Bruin, Peter C.
    Oudejans, Joost J.
    van der Groep, Petra
    Hinrichs, Bernd
    van Diest, Paul J.
    MODERN PATHOLOGY, 2012, 25 (03) : 398 - 404
  • [36] Introducing Molecular Subtyping of Breast Cancer Into the Clinic?
    Sorlie, Therese
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) : 1153 - 1154
  • [37] Breast cancer subtyping from plasma proteins
    Zhang, Fan
    Chen, Jake Y.
    BMC MEDICAL GENOMICS, 2013, 6
  • [38] Breast cancer subtyping from plasma proteins
    Fan Zhang
    Jake Y Chen
    BMC Medical Genomics, 6
  • [39] RT LAMP assay for the subtyping of breast cancer
    Lee, In Hee
    Kang, Byeongju
    Lee, Jeeyeon
    Jung, Jin Hyang
    Park, Ho Yong
    Park, Nora Jee-Young
    Park, Ji-Young
    Kim, Eun Ae
    Kang, Jieun
    Chae, Yee Soo
    Lee, Soo Jung
    CANCER RESEARCH, 2024, 84 (09)
  • [40] Molecular subtyping of breast cancer: ready to use?
    de Ronde, Jorma
    Wessels, Lodewyk
    Wesseling, Jelle
    LANCET ONCOLOGY, 2010, 11 (04): : 306 - 307